Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community PSA to shake your Topical Fin + Min

      in Finasteride/Dutasteride  10 upvotes 2 years ago
      The user realized they didn't shake their HappyHead Topical Fin + Min before use, leading to inconsistent application of Finasteride due to sediment at the bottle's bottom. They advise others to shake their topical hair loss treatments before use.

      community Dutasteride and anal with partner

      in Satire  119 upvotes 3 months ago
      Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

      community Has anyone tried this Ru58841 from Amazon ?

      in Product  3 upvotes 10 months ago
      RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.
      What kind of balding is this?

      community What kind of balding is this?

      in General  69 upvotes 1 year ago
      A 34-year-old male is experiencing hair loss on the sides of his head, with inflammation and itchiness, while the top remains thick. He is using topical dutasteride and keto shampoo to address the issue.

      community Topical Dutasteride And Sperm Quality ?

      in Finasteride/Dutasteride  1 upvotes 2 years ago
      A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.